Navidea biopharmaceuticals reports fourth quarter 2022 financial results

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the three-month and twelve-month periods ended december 31, 2022.
NAVB Ratings Summary
NAVB Quant Ranking